Navigation Links
Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
Date:2/1/2010

EMERYVILLE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has appointed Ted W. Love, M.D., Executive Vice President and Head of Research and Development.  In addition, Michael Kauffman, M.D., Ph.D., who has served as Interim Chief Medical Officer since November 2009, has been appointed Chief Medical Officer reporting to Dr. Love.  

In his new role, Dr. Love will report to the Chief Executive Officer and will be responsible for managing the research and development organization, including preclinical and clinical programs, regulatory affairs, quality assurance and control, and safety.  Dr. Kauffman, in addition to partnering with Dr. Love across the company's portfolio, will continue to play a lead role in the clinical development of Onyx's pipeline of next-generation proteasome inhibitors, including carfilzomib, which is currently in a Phase 2b trial for relapsed, refractory multiple myeloma.

"Ted is a strategic thinker with broad leadership and management experience and a track record of developing some of the most successful cancer therapies, making him the ideal person to lead our research and development program of innovative oncology candidates," said N. Anthony Coles, M.D., President and Chief Executive Officer of Onyx.  "Together, Ted and Michael bring highly complementary experience that spans solid tumor and hematologic cancers, and multiple drug classes and molecular pathways.  These appointments empower Onyx with world class R&D leadership as we deliver on our vision to transform the lives of cancer patients and their families wi
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
2. China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
3. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
4. Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
5. Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
6. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
7. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
8. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
9. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
10. Poniard Pharmaceuticals Announces $6.5 Million Financing
11. Titan Pharmaceuticals to Receive $3 Million Loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... ... 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised for ... diagnostics industry. BCC Research reveals in its new report that the market drivers of ... a growing need for better diagnostics as part of a molecular diagnostics trend. , ...
(Date:7/1/2015)... and BANGALORE, India , ... genomic profiling company that uses next generation sequencing technology ... Scott A. Storrer as chief executive officer. ... he will be responsible for all strategy, business expansion ... , who has served as Strand,s chairman and CEO ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... June 11 Cardium Therapeutics,(Amex: CXM ) ... at, http://www.anginaresearchstudy.com to provide patients, caregivers and,physicians ... clinical,study. The AWARE study is evaluating the therapeutic ... ischemia (insufficient blood flow,within the heart muscle) and ...
... Solution Available to Healthcare Organizations through CSC,s ... ... June 11 CSC (NYSE: CSC ) today,announced that ... the company,s FirstPortfolio offering.,FirstPoint streamlines a health organization,s document management,processes ...
... --- More than 30 years ago, when Northwestern University chemist ... never thought he would be using it to learn more ... including a watercolor recently featured in the museum,s exhibition "Watercolors ... watercolor "For to be a Farmer,s Boy," painted in 1887, ...
Cached Biology Technology:Cardium Launches New AWARE Clinical Study Website 2Cardium Launches New AWARE Clinical Study Website 3Cardium Launches New AWARE Clinical Study Website 4Cardium Launches New AWARE Clinical Study Website 5Cardium Launches New AWARE Clinical Study Website 6Cardium Launches New AWARE Clinical Study Website 7CSC Adds Content Management to Hosted Healthcare Offering 2Northwestern chemist investigates lost reds in Homer painting 2
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... Unless the IT industry adopts new energy-efficient technologies ... of being unable to contribute to growing the global ... findings come from an 18-month investigation by scholars at ... Singapore and Rice University,s Baker Institute for Public Policy ...
... SAN FRANCISCO, CAOctober 10, 2010Scientists at the Gladstone Institute ... associated with the storage of fat in the liver is ... (HCV). This discovery may offer a new strategy for treating ... throughout the world, and no vaccine is available to prevent ...
... - October 10, 2010 - Novocure reported today that ... a significant increase in survival time when tumor treating ... to previously reported outcomes for patients receiving chemotherapy alone. ... Winterthur Hospital Cancer center in Switzerland, presented the data ...
Cached Biology News:Half the productivity, twice the carbon 2Half the productivity, twice the carbon 3Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells 2Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer 2
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
... Purpose -- The Varian 1200 ... highest level of flexibility and ... affordable, easy-to-use system. The complete ... guarantees success with today's applications ...
Biology Products: